Elevated antibody titers in Abdala vaccinees evaluated by Elecsys® anti-SARS-CoV-2 S highly correlate with UMELISA SARS-CoV-2 ANTI RBD, ACE-2 binding inhibition and viral neutralization assaysGilda Lemos, Gerardo Guillén, Ariel Palenzuela-Díaz et al.|medRxiv|2021Cited by 8
Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3–18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study)Zurina Cinza-Estévez, Y. RodriguezGuevara, Sonia Resik et al.|EClinicalMedicine|2023Cited by 6
Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical TrialGilda Lemos, Gerardo Guillén, Yinet Barrese-Pérez et al.|Vaccines|2024Cited by 5
Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical TrialGilda Lemos, Gerardo Guillén, Yinet Barrese-Pérez et al.|Preprints.org|2024Cited by 2
Validation and clinical performance of a non-commercial ELISA for SARS-CoV-2 anti-RBD IgA antibodiesSheila Chávez-Valdés, Gilda Lemos, Ana K Marichal-Rodríguez et al.|Analytical Biochemistry|2025Cited by 1